Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,190.00
Bid: 12,210.00
Ask: 12,214.00
Change: 162.00 (1.35%)
Spread: 4.00 (0.033%)
Open: 12,036.00
High: 12,214.00
Low: 12,024.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 8-U.S. crude settles lower on worries about Coronavirus vaccine rollout

Fri, 29th Jan 2021 05:59

(New throughout, updates prices, market activity and comments
to settlement)

By Jessica Resnick-Ault

NEW YORK, Jan 29 (Reuters) - U.S. oil prices settled
slightly lower after trading in a tight range on Friday, as
investors worried about the lingering global pandemic and slow
vaccine rollouts.

The most active global Brent crude contract also
ended lower on concerns about vaccine distribution and the
efficacy of one vaccine.

"The vaccine numbers are just not there," said Bob Yawger,
director of energy futures at Mizuho in New York.

Oil markets have rallied about 50% since October on the back
of vaccine rollouts, but the emergence of COVID-19 variants has
fanned worries about economic weakness. Yawger said a U.S.
economic stimulus package may not come quickly enough to support
the market.

U.S. President Joe Biden urged Congress to take swift action
on a $1.9 trillion COVID-19 relief proposal.

"There is no time for any delays," Biden said. "It could
take a year longer to return to full employment if we don't act
and don't act now."

Global benchmark Brent crude futures for March
settled up 36 cents, or 0.6% a barrel, at $55.88. The Brent
March contract expires on Friday. The more active April contract
settled down 6 cents a barrel, at $55.04.

U.S. West Texas Intermediate (WTI) crude futures fell
14 cents, or 0.3%, to $52.20.

Both front-month Brent and WTI were on track to post a
weekly gain of less than 1%.

A Reuters poll showed oil prices are expected to hover
around current levels for much of 2021 before a recovery gains
traction towards year-end.

U.S. crude fell along with stock indexes, as investors
gauged the efficacy data of Johnson & Johnson's COVID-19
vaccine. The drugmaker's shares fell after it said its
single-dose vaccine was 72% effective in preventing COVID-19 in
the United States, with a lower rate of 66% observed globally.

Saudi Arabia is set to cut output by 1 million barrels per
day (bpd) in February and March. Compliance with output curbs by
the Organization of the Petroleum Exporting Countries and
allies, together known as OPEC+, improved in January.

OPEC oil output rose in January, a Reuters survey found,
after OPEC+ agreed to an easing of supply curbs.

However, the rise was less than the agreed amount, with an
involuntary drop in Nigerian exports limiting the increase.
(Reporting by Jessica Resnick-Ault in New York
Additional reporting by Bozorgmehr Sharafedin in London, Roslan
Khasawneh in Singapore and Sonali Paul in Melbourne
Editing by David Goodman, Louise Heavens, David Gregorio and
Richard Chang)

More News
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.